



ADVANCEMENTS IN OSMOTIC DRUG DELIVERY SYSTEMS FOR CHRONOTHERAPEUTIC APPLICATIONS: DESIGN STRATEGIES, FORMULATION VARIABLES, AND FUTURE PERSPECTIVES

**Yashpal Singh Solanki¹, Tanisha Arora², Deepa Patwa³, Harshveer Singh Jaitawat⁴,
Dr. Harshil Jagan⁵**

^{1,2,3}Assistant Professor, Department of Pharmaceutics, Sunrise College of Pharmacy, Udaipur, Rajasthan, India,

⁴Assistant Professor, Department of Pharmaceutical Chemistry, Sunrise College of Pharmacy, Udaipur, Rajasthan, India,

⁵Assistant Professor, Department of Pharmacology, Sunrise College of Pharmacy, Udaipur, Rajasthan, India

*Corresponding Author: Yashpal Singh Solanki

Article DOI: <https://doi.org/10.36713/epra29082>

DOI No: 10.36713/epra29082

ABSTRACT

Chronotherapeutic is the timed administration of drugs according to the body's internal clock which enhances the efficacy of the therapeutic and reduces the side effects of chrono pathological diseases like asthma, cardio-vascular diseases and rheumatoid arthritis among others [1,2]. There is a need for advanced drug delivery systems since the conventional dosage forms do not provide the intended time programmed or pulsatile release of drugs. Osmotic delivery systems for drugs (ODDS) are ideally strong systems, in which the drug release is controlled by osmotic pressure, independent of the surrounding fluid hydrodynamics and pH, hence predictable drug release [3,4].

It is in this regard that the book reviews the design, developmental evolution and formulation aspects of osmotic pumps for chronotherapeutic applications. The book provides an intricate evaluation of programmable drug delivery systems like push pull osmotic pumps (PPOP), time clock systems, capsule design, and multiarticulate osmotic systems with rupturable coating among others [5,6]. It also discusses the formulation factors including, the nature and number of osmotic agents, membrane's porosity and thickness, and polymer dynamics, and laser-drilled orifice and their impact on lag time and subsequent drug release rates [7].

The book also reviews the FDA-approved formulations, in-vitro in-vivo correlation and clinical cases, challenges associated with the manufacture of osmotic pumps systems including dose dumping and scale-up issues, 3D printing technologies and future perspectives of osmotic pumps as smart systems for time programmed drug delivery [8].

KEYWORDS: Chronotherapeutic; Osmotic Drug Delivery Systems; Pulsatile Release; Circadian Rhythm; Push-Pull Osmotic Pumps.

INTRODUCTION

The circadian rhythm, a highly synchronized biological clock, regulates a wide range of physiological and biochemical processes in the human body over a 24-hr period [1,6]. There are many chronic diseases, such as bronchial asthma, ischemic heart disease, hypertension, and rheumatoid arthritis, which have the pathophysiology with pronounced diurnal variations in the severity of symptoms [2,14]. In addition, such time-dependent fluctuations in biological systems are often not addressed by conventional drug delivery mechanisms which are designed to maintain drug plasma concentrations. This basic discordance has led to the emergence of chronotherapeutic, a clinical approach to align drug delivery with intrinsic biological rhythms to enhance therapeutic effectiveness and reduce systemic toxicity [1,2].

To optimize the chronotherapeutic profile, it is essential to develop a pulsatile or time-delayed drug release system [8,9]. The ideal oral dosage forms allow for rapid and complete release of the API after a predetermined delay. The matrix tablets and standard enteric-coated tablets have been investigated, but their release properties depend too much on the GI tract environment, such as GI motility, hydrodynamics, and pH. These factors are not easy to control, which resulted in poor reproducibility and caused unsatisfactory performance from both inter- and intra-subject variability for chrono pharmacotherapy.

To overcome the disadvantage of conventional dosage forms, Osmotic Drug Delivery Systems (ODDS) have been introduced as a prime system [3,4]. The main mechanism by which ODDS work is osmosis. The process involves using osmotic pressure to push off drug solutions or suspensions through a laser-drilled hole [7]. The most prominent characteristic of the ODD system is that it provides a reproducible release of the drug at a nearly constant rate that is largely independent of the surrounding environment [5].

Conventional ODDS (Osmotic Drug Delivery Systems) allow for zero-order drug release profiles; however, for the lag-time characteristics necessary for chronotherapeutic drug delivery, their design requirements had to undergo certain modifications [5]. In the last decade, several approaches were made to engineer new designs of the conventional ODDS. More recent concepts such as push-pull osmotic pumps, time-capsule systems, programmable port systems, and dosage forms utilizing rupturable semi-permeable membrane technologies have been introduced to fill the niche between continuous and time-controlled drug delivery systems [8,9].



Despite these innovations, the development of a chronotherapeutic osmotic pump is still a challenging biopharmaceutical problem due to the fact that critical formulation variables like active ingredient, osmotic agents, membrane plasticizers, coat thickness, and orifice size must be regulated to achieve the theoretically predicted lag-time profile corresponding to a certain chronotherapeutic target [7,10]. Hence, an overview of the recent design and formulation trends relevant to the chronological drug delivery systems is presented. Particular attention is given to the discussion of the recently developed concepts and design modifications, assessment of the formulation factors, and analysis of the in-vivo performance. The review also focuses on examining the possibilities of implementing novel advanced manufacturing technologies such as 3D printing [15]. It is suggested that the information provided in this review will aid in future development of time-controlled osmotic pumps.

Biological Rationale (Chronotherapeutic):

The rationale of chronotherapeutic is based in chronobiology, the science of biological rhythms and their mechanisms [1]. The body does not keep a steady state but periodically varies certain physiological variables (blood pressure, heart rate, secretion of gastric juices, hormones etc.) throughout the day [6]. As a result, the pharmacokinetic (absorption, distribution, metabolism and excretion) and pharmacodynamic (drug-receptor interactions and therapeutic effects) properties of many drugs display marked circadian variations. A standard approach to therapy is to maintain constant concentration of a drug in order to keep up with the variable concentration of a disease state. A chronotherapy seeks to make use of the circadian variations of biological functions by timing drug administration such that the concentration of a drug in tissues follows the physiological changes related to the disease [1,2].

Chrono pathological Conditions Requiring Pulsatile Delivery [2,14]

Disease/Condition Circadian Pattern (Exacerbation) Biological Rationale Target Drug Release Profile

Bronchial Asthma Midnight to 4:00 AM Epinephrine and cortisol levels fall overnight while histamine and cholinergic tone rise, causing bronchoconstriction. Evening administration with 4-6 Hr lag time to release bronchodilators before midnight.

Cardiovascular Disease (Hypertension/Angina) 6:00 AM to 12:00 PM Blood pressure and heart rate surge upon waking due to increased sympathetic nervous system activity and catecholamine release. Bedtime administration with 6-8 Hr lag time for morning peak plasma levels.

Rheumatoid Arthritis Morning upon awakening Pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) peak during the night resulting in severe morning joint stiffness and pain. Bedtime dosing with delayed release to suppress overnight inflammatory cascades.

Peptic Ulcer Disease Nighttime Basal gastric acid secretion peaks at night while the stomach is empty, exacerbating mucosal irritation. Evening administration with targeted nighttime delivery of H2 antagonists/PPIs.

Connecting Biological Rationale to Osmotic Delivery

In order to make this sort of rationale actually workable in the clinic, dosage forms should be able to supply a certain "lag phase" and then a specific drug release pattern [9]. Conventional delayed release dosage forms utilize enteric coatings that are sensitive to pH, so they are highly dependent on the inter-individual variations in gastric emptying and intestinal motility. Since circadian driven conditions require the precise timing to avoid a critical event, the delivery system has to be absolutely reliable. Osmotic pumps fulfil this biological requirement by the virtue of osmotic pressure that drives drug release, thus, making the lag time design a mathematical and physiologically independent exercise [3,4].

Fundamentals of Osmotic Pumps:

Osmotic drug delivery systems (ODDS) use osmosis and hydrostatic pressure to allow for zero-order release of drugs [3]. This is the primary difference between ODDS and standard matrix tablets. The drug delivery process is independent of physiological factors or the content of the patient's diet [4,5].

The liquid from the gastrointestinal tract infiltrates the tablet core, thereby dissolving the drug and osmogenes to form an osmotic gradient. The resulting solution is then expelled through a specific aperture. Drug Delivery Rate Equation [3]

$$dV/dt = \frac{A \cdot k}{h} (\Delta\pi - \Delta P)$$

- dV/dt : Rate of water entry into the tablet (determines the delivery rate)
- A : Area of the membrane
- k : Membrane coefficient
- h : Thickness of the membrane
- $\Delta\pi$: Osmotic pressure difference
- ΔP : Hydrostatic pressure difference

Key Components of an Osmotic Pump [5,7]

Element	Core Function	Common Materials
Semi-Permeable Membrane (SPM)	Acts as a rigid barrier that allows water to penetrate while blocking the drug from escaping.	Cellulose acetate
Osmotic Agents (osmogen)	Dissolves inside the tablet to create the required osmotic gradient ($\Delta\pi$).	Inorganic salts (NaCl, KCl), Sugars (Mannitol, Sucrose)



Delivery Orifice	A small hole (< 1 mm) created via laser or mechanical indentation. It releases the drug under pressure without allowing passive leakage.	N/A
Plasticizers & Flux Regulators	Added to the SPM coating to reduce polymer cross-linking, increasing flexibility and preventing the membrane from bursting.	PEG, Triacetin

While elementary osmotic pumps (EOP) are ideal for zero-order release, they cannot control the specific *time* of drug release, which limits their use in chrono pharmaceutical formulations without further design modifications.

Design Strategies for Chronotherapeutic Osmotic Pumps (e.g., Port systems, Rupturable coatings, Push-Pull designs) [8,9]

In order to achieve the exact lag times and pulsatile release kinetics required by chronotherapeutic, conventional osmotic designs have been reworked to include physical barriers, expandable hydrogels, rupturable membranes, etc.

1. Programmable Ports

The Port System is an osmotic-based capsule designed to produce pulsatile drug release profiles upon ingestion [8]. The design comprises a hard gelatine capsule with a semi-permeable membrane (SPM) covering which contains the drug along with an osmotic agent, sealed by a water-insoluble plug either of lipidic or hydrogel nature at the end of the capsule's opening.

As the gastrointestinal fluids penetrate through the SPM, the osmotic pressure inside the capsule increases.

The lag time is determined by the thickness and the composition of the plug. Once the pressure is high enough to push out the stopper, a sudden burst of the drug is released.

2. Push-Pull Osmotic Pumps with Delayed Coatings

Push-Pull Osmotic Pumps (PPOPs) are traditionally used to release poorly-soluble molecules in a zero-order release manner [5,9]. However, certain modifications to the system can allow for the generation of chronotherapeutic profiles. The core of such PPOPs is usually a biconvex tablet, containing two distinctive regions: the drug and osmogen-containing layer, and the pusher layer made of a highly-swelling polymer, such as Polyethylene Oxide.

The principle of operation of PPOPs is based on the osmotic pressure generated by the hydration of the pusher layer, which deforms the pusher membrane, forcing the drug suspension out of the PPOP's orifice.

The creation of a lag-time in PPOPs is achieved by the additional coating of the whole system with either erodible polymers (e.g., HPMC) or enteric polymers, depending on the desired site of action. Such coatings are designed to be gradually eroded upon ingestion, allowing the osmotic pump to begin its function at a predetermined time.

3. Pulsatile Osmotic Pumps with Rupturable Coatings

The design of choice for generating pulsatile release profiles is the osmotic pump with rupturable membrane [8]. In contrast to the traditionally used drilled membranes, such PPA devices utilize a rupturable coating which fails due to the high internal osmotic pressure, thus allowing the drug to be released in a sudden pulse.

The core of the system is a tablet containing the drug heavily loaded with strong osmotic agents and super disintegrants like croscarmellose sodium.

The formation of the high osmotic pressure is achieved by the incorporation of water into the tablet's core, which causes the membrane to rupture.

The SPM of the tablet is formulated to have a specific tensile strength that will be overcome by the built osmotic pressure at a specific point in time. This tensile strength is determined by the thickness and mechanical properties of the SPM. The lag time can be varied by the manipulation of these variables.

4. Time-Clock Capsular Systems

The time-clock capsule is another system designed to generate delayed drug release [8]. The construction of the device is similar to the port system in that it utilizes a water-insoluble capsule with a stopper. However, the lag time is achieved using a combination of a hydrogel plug and SPM. In this design, the water penetration through the SPM is slowed down by the inclusion of a swellable hydrogel stopper (often made from cross-linked PEG or HPMC).

The rate of water penetration through the hydrogel stopper determines the lag time: the slower the water enters the capsule, the longer the time before the drug is released. The time period is linear to the molecular weight of the polymer and the distance of the stopper inside the capsule.

5. Multi-Particulate Osmotic Systems

Instead of a single capsule, multi-particulate osmotic systems use dozens or hundreds of small pellets, each behaving as an individual osmotic pump [9]. Using such systems, chronotherapeutic release profiles can be easily engineered by varying the thickness of the SPM of each pellet during fabrication. The combination of two types of pellets with different lag-times in a single capsule can allow for the construction of a release profile with two peaks, appropriate for the treatment of conditions such as rheumatoid arthritis.

**Formulation Variables in Osmotic Delivery Systems [7]**

Formulation Variables, focusing on how osmotic agents, membrane thickness, and orifice size affect the lag time and release rate.

The precise programming of lag times and subsequent pulsatile release in chronotherapeutic osmotic pumps is a function of the meticulous optimization of specific formulation variables. Manipulation of these parameters allows formulators to dictate the precise hydration kinetics and internal hydrostatic pressure required to trigger drug release.

Key Formulation Variables

Formulation Variable	Mechanism of Action	Effect on Lag Time	Effect on Release Rate
Osmotic Agents (Osmogens)	Generates the internal osmotic pressure gradient ($\Delta\pi$). High-solubility salts (NaCl, KCl) or sugars (mannitol) drive rapid water influx.	Decreases. Higher osmotic pressure accelerates fluid penetration, shortening the dormant phase.	Increases. Faster water influx leads to a higher hydrostatic extrusion force.
SPM Thickness	Acts as a physical barrier. Controls the distance water must travel to initiate the osmotic core hydration.	Increases. A thicker membrane significantly delays core hydration and pressure buildup.	Decreases. The rate of fluid influx is inversely proportional to membrane thickness.
Pore Formers (e.g., PEG, Sorbitol)	Dissolves upon contact with aqueous media, creating micro-channels in the cellulose acetate SPM.	Decreases. Rapid formation of micro-pores allows faster fluid penetration.	Increases. Higher membrane porosity directly enhances water permeability (k).
Delivery Orifice Diameter	Provides the exit pathway for the drug suspension. Typically, 0.1 to 1.0 mm.	Negligible. Orifice size primarily governs the extrusion phase, not the initial water influx.	Modulates Profile. If too small, internal pressure causes erratic bursts; if too large, premature diffusion occurs.
Expandable Hydrogels (Push Layer)	Polymeric agents (e.g., Polyethylene Oxide) that swell upon hydration to physically expel the drug layer.	Increases. The polymer requires a specific hydration period before swelling reaches the threshold to push.	Maintains Zero-Order/Pulse. Dictates the force and duration of the extrusion phase.

The selection of the osmotic agent is often the most critical initial step. Formulators must match the osmotic activity of the core with the desired lag time [7]. For instance, in rupturable osmotic pumps, blending highly osmotic agents with super disintegrants ensures that once the lag phase (controlled by SPM thickness) concludes, the internal pressure violently overcomes the membrane's tensile strength, delivering an immediate, complete pulse of the drug.

Conversely, in push-pull systems designed for delayed-onset continuous release, the molecular weight of the hydrogel in the push layer is adjusted. Higher molecular weight polymers hydrate more slowly, effectively extending the lag time before they exert sufficient mechanical force to extrude the active pharmaceutical ingredient.

Evaluation Parameters (like IVIVC) and Recent Marketed Formulations / Case Studies.

To establish the exact lag times and release rates needed for chronotherapy, osmotic pumps are subjected to rigorous specialized evaluations before their clinical implementation [11,12].

6. Evaluation Parameters**In-Vitro Dissolution Testing**

Unlike conventional matrix-type tablets where dose release is highly dependent on physiological conditions, osmotic pumps are characterized by a reduced dependence on the properties of the gastrointestinal tract [4,11]. Typically, dissolution studies are carried out in accordance with USP Apparatus II (Paddle) or USP Apparatus VII (Reciprocating Holder). To demonstrate the independence of the dose release from physiological conditions, the dissolution of the pump is examined at different pH levels, agitation rates, and osmolarity.

pH-Independence: Dissolution in acidic (pH 1.2) and alkaline (pH 6.8) medium to ensure that the rate of drug release is independent from the pH of the gastrointestinal tract.

Agitation-Independence: Dissolution at different agitation rates (50, 100, 150) rpm to determine the effect of hydrodynamic forces on the operation of the pump.



Osmolarity: Dissolution at different osmotic pressures by using various sucrose/mannitol solutions to mimic a wide range of hydrostatic pressures in the interstitial fluid.

In-Vitro / In-Vivo Correlation, IVIVC

For Chronotherapeutic drug delivery systems, it is essential to establish a reliable In-Vitro / In-Vivo Correlation (IVIVC) at the Level A [11]. This implies that the in-vitro dissolution rate is directly related to the in-vivo drug input rate with a mathematical function that passes through the observed data points. For osmotic pumps, due to their unique mechanism of drug delivery, the in-vitro lag time corresponds to the in-vivo lag time. Additionally, due to either constant delivery rate (in case of push-type pumps) or an ascending delivery rate (in case of push-pull pumps), their IVIVC is relatively straightforward as compared to other formulations [11]. Thus, there is no need for extensive pharmacokinetic trials during the optimization of chronotherapeutic formulations.

Chronotherapy Marketed Products and Their Characteristics [12]

There are several FDA-approved formulations currently on the market that use various forms of osmotic pumps to achieve a chronotherapeutic effect. Brand Name Drug Osmotic Technology Indication / Therapeutic Target Chronotherapeutic Release Profile Covera-HS Verapamil HCl COER-24 (Controlled-Onset Extended Release) Hypertension / Angina: reduction of nocturnal increase of blood pressure and heart rate 4-5 hour lag time followed by an extended release Concerta Methylphenidate Push-Pull Osmotic Pump (PPOP / OROS) ADHD: address the morning attention deficit and reduce the need for dose escalation in school hours Immediate release of the overcoat followed by an increasing dose rate throughout the day Glucitols XL Glipizide Push-Pull Osmotic Pump (GITS) Type II Diabetes: maintenance of glycaemic control throughout the day with minimum risk of hypoglycaemia Continuous zero-order release without dependence on GI motility Invega Paliperidone OROS Tri-layer Pump Schizophrenia: maintenance of dose throughout the day without peak concentrations for prevention of relapse and reduction of side effects Ascending dose rate throughout the day with reduced initial dose to prevent orthostatic hypotension

Covera-HS Chronotherapeutic Case Study

Covera-HS is considered the prime example of a chronotherapeutic drug delivery system based on an osmotic pump mechanism [13]. Its active ingredient is Verapamil Hydrochloride. This formulation uses ALZA's COER-24 technology which incorporates a push pump coated with a special film that is resistant to gastric fluids. An innovative approach used in this system is the addition of a special coating over the pump membrane to introduce a controlled lag time. By modifying the thickness of the coating and the polymer composition, the manufacturer was able to delay the start of the dose delivery by 4-5 hours after oral administration [13]. Such delay allows the patient to avoid the increased cardiovascular risk during the early morning hours when blood pressure typically reaches its peak.

Challenges & Future Perspectives

Despite their clinical and therapeutic advantages, contemporary chronotherapeutic osmotic pumps face several challenges and barriers to commercialization [14,16].

Current Challenges and Barriers to Commercialization:

Manufacturing complexity and cost: The fabrication of multilayer osmotic systems, application of semi-permeable membrane (SPM), and laser drilling technology require sophisticated and expensive equipment. This increases fabrication costs, limiting the application of chronotherapy to niche markets compared to conventional matrix tablets.

Dose dumping potential: The failure of the SPM or its chewing by the patient can result in an uncontrolled dose of the drug. Additionally, the consumption of highly alcoholic beverages with erodible-coated osmotic systems can also cause similar physiological effects, which can be life-threatening.

Colonic fluid environment: For drugs with long lag-time (8–10 h), the colon receives the osmotic pump at the end of the small intestine. The colonic fluid is significantly more viscous and has a lower volume than that of the small intestine. This may affect the hydrodynamic pressure and hinder water influx into the system.

Drug solubility: The active pharmaceutical ingredient in the osmotic pump must ideally be highly soluble or easily suspended in water. Thus, the delivery of lipophilic drugs (BCS class II and IV) requires the addition of solubilizing agents or particle reduction techniques such as canonization, which compromises the available space in the capsule/tablet core.

Future Development and Trends:

3D printing (additive manufacturing): 3D printing technologies such as fused deposition modelling can be used to fabricate advanced programmable and predictable osmotic systems [15]. This emerging innovation allows the fabrication of 3D-printed tablets with a defined pore structure and thickness of the micro-perforated membrane without the need for laser drilling technology. It reduces the cost of fabrication and allows personalized or patient-tailored chronotherapeutic drug delivery based on the physiological data of each individual [15].

Artificial intelligence (AI): AI can aid in predicting and simulating complicated physicochemical processes such as lag-time and release rate of the drug from the osmotic system. Such technologies are critical in reducing the trial-and-error approaches in the design process.



Conclusion

Chronotherapeutic is a new paradigm in the clinical management of disease, as it recognizes the time component as an integral part of drug administration [1,2]. Conventional dosage forms are ineffective in managing disease progression partly due to the inconsistent physiology of the gastrointestinal tract. Osmotic drug delivery systems offer a reliable and predictable option for time-controlled release of therapeutics in a programmed manner [5,9]. By employing novel approaches such as programmable ports, rupturable membranes, delayed-coating push-pull pumps, and smart polymers, pharmaceutical scientists can successfully mimic the circadian rhythm and achieve optimal clinical benefit. The lag-time of the osmotic pump can be manipulated to coincide with the peak onset of targeted diseases such as asthma, hypertension, and rheumatoid arthritis. Although manufacturing complexity and drug solubility present some of the main obstacles to wider application of osmotic pumps in chronotherapy, additive manufacturing and AI-assisted design can resolve most of these issues [15]. Overall, future developments in chronotherapeutic osmotic pumps will play a critical role in clinical pharmacology and therapeutics.

REFERENCES

1. Smolensky, M. H., & Peppas, N. A. (2007). Chronobiology, drug delivery, and chronotherapeutics. *Advanced Drug Delivery Reviews*, 59(9-10), 828-851.
2. Youan, B. B. C. (2004). Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? *Journal of Controlled Release*, 98(3), 337-353.
3. Theeuwes, F. (1975). Elementary osmotic pump. *Journal of Pharmaceutical Sciences*, 64(12), 1987-1991.
4. Santus, G., & Baker, R. W. (1995). Osmotic drug delivery: a review of the patent literature. *Journal of Controlled Release*, 35(1), 1-21.
5. Verma, R. K., Mishra, B., & Garg, S. (2000). Osmotically controlled oral drug delivery. *Drug Development and Industrial Pharmacy*, 26(7), 695-708.
6. Lemmer, B. (1991). Circadian rhythms and drug delivery. *Journal of Controlled Release*, 16(1-2), 63-74.
7. Malaterre, V., et al. (2009). Oral osmotically driven systems: 30 years of development and clinical use. *European Journal of Pharmaceutics and Biopharmaceutics*, 73(3), 311-323.
8. Maroni, A., Zema, L., Cerea, M., & Sangalli, M. E. (2010). Time-controlled release technology: a review of current concepts and systems. *Expert Opinion on Drug Delivery*, 7(12), 1335-1350.
9. Taneja, R., & Gupta, S. (2016). Osmotic pulsatile drug delivery system. *International Journal of Pharmaceutical Sciences and Research*, 7(2), 543-553.
10. Herrlich, S., et al. (2012). Osmotic micropumps for drug delivery. *Advanced Drug Delivery Reviews*, 64(14), 1617-1627.
11. Emami, J. (2006). In vitro-in vivo correlation: from theory to applications. *Journal of Pharmacy & Pharmaceutical Sciences*, 9(2), 169-189.
12. Conley, R., et al. (2006). Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. *Current Medical Research and Opinion*, 22(10), 1879-1892.
13. White, W. B., et al. (1995). A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. *American Journal of Cardiology*, 76(4), 213-219.
14. Saigal, N., Baboota, S., Ahuja, A., & Ali, J. (2009). Chronomodulated drug delivery systems. *Journal of Controlled Release*, 137(1).
15. Cui, M., et al. (2024). Fabrication of osmotic pump tablets utilizing semisolid extrusion 3D printing. *International Journal of Pharmaceutics*, 660, 123712.
16. Gupta, B. P., Thakur, N., Jain, N. P., Banweer, J., & Jain, S. (2010). Osmotically controlled drug delivery system with associated drugs. *Journal of Pharmacy & Pharmaceutical Sciences*, 13(4), 571-588.